These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18540370)

  • 1. [Apheresis therapy in Guillain-Barré syndrome].
    Nagayama H; Katayama Y
    Nihon Rinsho; 2008 Jun; 66(6):1195-9. PubMed ID: 18540370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barré syndrome.
    Okamiya S; Ogino M; Ogino Y; Irie S; Kanazawa N; Saito T; Sakai F
    Ther Apher Dial; 2004 Jun; 8(3):248-53. PubMed ID: 15154879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
    Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma exchange versus double filtration plasmapheresis in the treatment of Guillain-Barré syndrome.
    Lyu RK; Chen WH; Hsieh ST
    Ther Apher; 2002 Apr; 6(2):163-6. PubMed ID: 11982959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guillain-Barré syndrome treated by membrane plasma exchange and/or immunoadsorption.
    Marn Pernat A; Buturović-Ponikvar J; Svigelj V; Ponikvar R
    Ther Apher Dial; 2009 Aug; 13(4):310-3. PubMed ID: 19695065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Removal ability of immunoglobulins in plasma exchange and double-filtration plasmapheresis].
    Tagawa Y; Yuki N
    Rinsho Shinkeigaku; 1997 May; 37(5):410-2. PubMed ID: 9294330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement.
    Dada MA; Kaplan AA
    Ther Apher Dial; 2004 Oct; 8(5):409-12. PubMed ID: 15663537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of anti-glycolipid antibody-associated neuropathy].
    Yuki N
    Rinsho Shinkeigaku; 1999 Dec; 39(12):1232-4. PubMed ID: 10791085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Guillain-Barré syndrome and CIDP.
    van Doorn PA
    J Peripher Nerv Syst; 2005 Jun; 10(2):113-27. PubMed ID: 15958124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances of therapeutic apheresis in Guillain-Barré syndrome.
    Haupt WF
    Ther Apher; 2000 Aug; 4(4):271-4. PubMed ID: 10975472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravenous immunoglobulin therapy for Guillain-Barré syndrome in Japan: changes in treatment after its inclusion in health insurance coverage].
    Nishimoto Y; Yuki N
    Rinsho Shinkeigaku; 2004 Sep; 44(9):633-5. PubMed ID: 15515710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin and Guillain-Barré syndrome.
    Harel M; Shoenfeld Y
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):281-7. PubMed ID: 16391403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.
    Shahrizaila N; Yuki N
    Expert Opin Pharmacother; 2011 Jul; 12(10):1551-60. PubMed ID: 21473704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative study of the efficacy of plasma exchange, immunoadsorption plasmapheresis and corticosteroid administration in the treatment of Guillain-Barré syndrome].
    Yamazaki M; Koh CS; Hanyu N; Sakai T; Inoue A; Yanagisawa N
    Arerugi; 1995 Apr; 44(4):498-502. PubMed ID: 7598643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin.
    Tsai CP; Wang KC; Liu CY; Sheng WY; Lee TC
    J Clin Neurosci; 2007 Jul; 14(7):625-9. PubMed ID: 17532498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of Guillain-Barré Syndrome].
    Nomura K
    Brain Nerve; 2015 Nov; 67(11):1397-410. PubMed ID: 26560955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing outcome in Guillain-Barré Syndrome: comparison of plasma adsorption against other treatments.
    Seta T; Nagayama H; Katsura K; Hamamoto M; Araki T; Yokochi M; Utsumi K; Katayama Y
    Clin Neurol Neurosurg; 2005 Oct; 107(6):491-6. PubMed ID: 16202823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome.
    Ye Y; Li SL; Li YJ
    Transfus Med; 2015 Apr; 25(2):79-84. PubMed ID: 25515056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunoglobulin therapy of neuromuscular diseases].
    Schuchardt V
    Nervenarzt; 1993 Feb; 64(2):91-7. PubMed ID: 8450900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Novel Therapeutic Interventions in Guillain-Barré Syndrome: Review and Future Perspective].
    Misawa S
    Brain Nerve; 2015 Nov; 67(11):1421-8. PubMed ID: 26560957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.